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Fragment-based de novo design of 
a cystathionine γ-lyase selective 
inhibitor blocking hydrogen sulfide 
production
Angela Corvino1,5, Beatrice Severino1, Ferdinando Fiorino1, Francesco Frecentese1, 
Elisa Magli1, Elisa Perissutti1, Vincenzo Santagada1, Mariarosaria Bucci1, Giuseppe Cirino1, 
Geoff Kelly2, Luigi Servillo3, Grzegorz Popowicz4, Annalisa Pastore5 & Giuseppe Caliendo1
Hydrogen sulfide is an essential catabolite that intervenes in the pathophysiology of several diseases 
from hypertension to stroke, diabetes and pancreatitis. It is endogenously synthesized mainly by two 
pyridoxal-5′-phosphate-dependent enzymes involved in L-cysteine metabolism: cystathionine-ß-
synthase (CBS) and cystathionine-γ-lyase (CSE). Research in this field is currently impaired by the lack 
of pharmacological tools such as selective enzymatic inhibitors that could target specifically only one 
of these pathways. We used a novel approach based on a hybrid method that includes drug design, 
synthetic biology, metabolomics and pharmacological assays to rationally design a new inhibitor 
selective for the CSE enzyme. The identification of this compound opens new frontiers towards a better 
understanding of the role of CSE over CBS in the pathophysiology of diseases where a role for the H2S 
pathway has been proposed and the development of new lead compounds that could target the CSE 
enzyme.
Hydrogen sulfide (H2S), a colorless, flammable, water soluble gas with the characteristic smell of rotten eggs, 
has emerged as an important gaseous signaling molecule playing numerous roles in health and disease, 
along with CO and NO1. Enzymatically generated H2S is mainly derived from two pyridoxal-5′ -phosphate 
(PLP)-dependent enzymes responsible for the metabolism of L-cysteine (L-Cys): cystathionine-β -synthase (CBS) 
and cystathionine-γ -lyase (CSE)2. A third pathway that catalyses the production of H2S from L-Cys via the com-
bined action of 3-mercaptopyruvate sulfurtransferase and cysteine aminotransferase has also been described3. 
This pathway is less well characterized and its role in determining the H2S levels in tissues still poorly understood.
CBS and CSE are cytosolic enzymes which catalyse several H2S-generating reactions which convert L-Cys 
and/or homocysteine as substrates to L-cystathionine and pyruvate respectively4–6. CBS was also originally con-
sidered to be the predominant enzyme for H2S production in the brain, indeed it is preferentially expressed in 
radial glia/astrocytes of adult and developing mouse brain7,8, whereas H2S synthesis in the heart and vasculature 
was attributed to CSE9. More recent studies with improved markers have provided a broader picture of enzyme 
distribution. Because of the co-presence of both enzymes in specific pathway it is important to find inhibitors that 
selectively target only one enzyme.
The most commonly used agents to inhibit H2S biosynthesis include propargylglycine (PAG), β -cyanoalanine 
(BCA) and aminooxyacetic acid (AOAA)10,11. PAG is described as CSE selective inhibitor in fact it will not inhibit 
recombinant CBS even if used at 10 mM12; moreover the crystal structure of the covalent complex PAG-CSE is 
the only described so far13. However all of these compounds have a relatively low potency and cell permeability 
and are used at high concentrations (mM)11. L-aminoethoxyvinylglycine (AVG) was also recently described as 
a potentially more potent and selective CSE inhibitor12 but its mechanism is still uncharacterised. The inherent 
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flexibility of AVG makes it in fact difficult to rationalise the mode of binding of this compound until a crystal 
structure of its complex with CSE becomes available. Lack of biological data assessing the role of this compound 
in cell culture, tissue baths and in vivo further studies have also discouraged an interest on AVG, leaving PAG as 
the reference usually considered.
The possibility to inhibit selectively only one of these enzymes has tremendous therapeutic potentialities. 
CBS inhibition has for instance been suggested as a potential therapeutic to the treatment of ischemic injury. 
Particularly interesting would be to be able to inhibit selectively the CSE pathway since this possibility would 
have important consequences in several pathologies, e.g. asthma and hemorrhagic shock. PAG, for instance, has 
been shown to inhibit H2S CSE-mediated production in animal models and to accelerate recovery of blood pres-
sure after hemorrhagic shock14. PAG was also shown to prevent the increase in plasma levels of markers of liver 
and pancreas injury, reduce the tissue content of myeloperoxidase15 with consequent significant prolongation of 
animal survival16. An important challenge which holds the promise to allow a much better comprehension of the 
H2S metabolism and that could be used for therapeutic purposes is thus the search for selective inhibitors able to 
block only one of the two enzymes and the establishment of the mechanism of interaction. However, the goal of 
finding such inhibitor is not an easy task given the similarity between the substrates and the mechanism involved 
in the enzymatic activity of the two enzymes.
We set with the aim of producing new and more selective inhibitors of CSE. Using a semi-rational in silico 
drug screening, we went through the synthesis and structural characterization of a selective CSE inhibitor. We 
tested the new compounds in tissue using an ex vivo assay with intact rat aortic rings. The compound show-
ing maximal inhibitory effects in this test is an oxothiazolidine derivative. The effects of this compound on the 
enzyme kinetics were further tested in vitro on the purified enzymes using a metabolomics approach based on 
nuclear magnetic resonance techniques. By setting up complementary and more comprehensive ex vivo and in 
vitro assays, we also established a more accurate way to study the H2S pathway and demonstrated the limitations 
of drawing conclusions only on the basis of the methylene blue assay, the most commonly used methodology 
for this purpose17,18. We could conclusively prove that the identified compound has properties of a new selective 
inhibitor of CSE. Our results bear crucial bio-technological and pathophysiological implications which will help 
further studies of the H2S pathway.
Results and Discussion
Rationale of the design of the new compounds. We first carried out a preliminary in silico analysis 
of the structures of the two enzymes to understand the geometric properties of the active sites. Although both 
homo-tetrameric and PLP bound, their sequences and structures are very different. In CSE, essential for the reac-
tion mechanism is a PLP covalently attached to Lys212 and stabilized by π -stacking interactions with the ring of 
Tyr114. In the complex with the inhibitor PAG, this is covalently bound to Tyr114 as a vinylether13. The amino 
and carboxyl groups of PAG form hydrogen bonds with Glu339 and with Arg119 and Arg62 from the adjacent 
monomer respectively. In CBS, PLP is bound to Lys11919,20 and is surrounded mostly by small amino acids, such 
as Ser349 and Asn149.
Informed by this structural analysis, we used a fragment-based approach in which we fused the structural 
features of the substrate cysteine with those of already known CSE inhibitors. We started by commercially avail-
able cysteine derivatives already used as substitutes of cysteine and selected L-thiazolidine-4-carboxylic acid and 
L-2-oxothiazolidine-4-carboxylic acid (indicated as compounds 1 and 2 in Table 1). We added to these scaffolds a 
propargyl group in α -carboxyl position since this structural element is essential in the proposed PAG mechanism 
of inhibition13 (compounds 1a and 2a). Independently, we considered the commercially available L-2-amino-3-
(thiophen-2-yl)propanoic acid and 5-amino-2-hydroxybenzoic acid which were interesting because the thiazo-
lidine moiety is substituted by aromatic groups (compounds 3 and 4). We reasoned that an important part of the 





Table 1. Chemical formulas of the compounds commercially available (left two columns) and synthesized 
for the present work (right two columns).
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CSE active site is constituted by Tyr114 and PLP which form π -stacking interaction. The presence of an aromatic 
group could thus facilitate interaction of the new compound21. We thus attached a propargyl moiety to these scaf-
folds obtaining compounds 3a and 4a. This allowed us to have novel molecular entities which fuse the structural 
features of both cysteine and the CSE inhibitor PAG.
Pharmacological assays suggest compound 2a as an inhibitor. The inhibitory properties of the 
commercially available compounds 1–4 and their newly synthesized derivatives were tested by an ex vivo assay 
on rat aortic rings by which the inhibitory activity on L-cysteine induced vasorelaxation was probed. All com-
pounds reduced L-Cys induced vasorelaxation, with compounds 2, 3 and 4 showing a higher inhibitory activity 
(for the Emax values refer to Suppl. Information) (Fig. 1A). Incubation of aortic rings with compound 1a did not 
affect the L-cysteine induced vasorelaxation. In contrast, compound 2a completely abrogated L-cysteine-induced 
vasorelaxation at a concentration of 100 μ M (Fig. 1B). An inhibitory effect was observed also with compound 
3a. However, as compared to 2a, compound 3a was unable to completely abrogate relaxation even at the highest 
concentration tested (1 mM). Compound 4a, tested at a lower concentration (10 μ M) because of its limited sol-
ubility, significantly inhibited L-cysteine induced vasorelaxation. However, its solubility limits the potential use 
of this compound as an inhibitor and makes it difficult to assay the compound in aqueous media in a vast range 
of concentrations.
These results showed that only conversion of compound 2 into the propargyl derivative 2a results in a com-
pound with good solubility which leads to an improvement of the inhibitory activity.
The inhibitory effect of compound 2a is direct and higher than that of known inhibitors. 
Compound 2a, which shows appreciable inhibition, was tested by the well-known methylene blue assay which 
measures H2S production (Fig. 2). Under basal conditions, tissue homogenates produced 1.4 ± 0.1% nmol of 
H2S per mg of protein. H2S production was stimulated by adding exogenous L-Cys into the vehicle, as routinely 
performed in this kind of experiment22,23. The modification doubled H2S production. Incubation with compound 
2a significantly inhibited the increased H2S production stimulated by L-Cys showing an effect comparable to that 
obtained with PAG but at a lower dose (100 μ M for compound 2a and 10 mM for PAG). We also compared the 
inhibitory activity of compound 2a with that of PAG (Fig. 3A,B) by using isolated aortic rings.
Incubation with compound 2a completely abrogated L-cysteine-induced vasorelaxation, while PAG reduced 
but not completely abrogated L-cysteine-induced vasorelaxation, despite the compound was tested at a higher 
concentration (10 mM and 100 μ M for PAG and 2a respectively).
To compare the efficacy of the two inhibitors, IC50 values were calculated determining the effect on the aorta 
rings relaxation in semilogarithmic scale at three different concentrations of the tested compounds. The obtained 
results, expressed as percent of relaxation (Fig. 3) allowed us to get the IC50 values. We obtained 3.3 ± 0.3 mM 
for PAG and 31.6 ± 0.6 μ M for the compound 2a indicating a two order magnitude improvement of the latter as 
compared to PAG.
These results propose compound 2a as a more potent inhibitor than previously known ones.
To estimate the plasma membrane crossing properties of the new inhibitor we calculated the partition 
n-octanol/aqueous phase coefficients (Log PN values) of the neutral form of 2a (c log P = 0.27) as compared to 
PAG (c log P = − 3.02) where logP is a theoretically calculated lipophilicity parameter that refers to the partition 
coefficient (P) in n-octanol/water of the neutral species. This tells us that the compound 2a is more hydrophobic 
than PAG and this property justifies the higher concentration (10 mM) of PAG required to cross the membranes 
and to exert, consequently, a maximal inhibitory effect.
Figure 1. Effect of the various compounds on L-cysteine-induced vasorelaxation. (A) Commercially 
available compounds (B) Synthesized compounds 1a–3a and 4a. Each group of experiments was carried  
out on 4 rings harvested from different animals to obtain a more representative averaging. Vehicle, water.
www.nature.com/scientificreports/
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We also tested the importance of the propargyl group by substituting this with a propyl group which bears 
approximately the same volume, although having a different geometry (compound 2b). When we tested this 
compound on rat aortic rings (Figure S3 of Suppl. Information), we observed no inhibitory effects indicating that 
the propargyl group is essential.
Inhibition is caused by the direct and selective interaction with the CSE enzyme. The effects of 
the selected compound were then tested on the purified recombinant CSE and CBS enzymes as this is the only 
way to prove that the effects observed in ex vivo assays are solely the consequence of a direct and specific inter-
action between the compound and the enzymes. The CBS and CSE enzymes were first expressed in Escherichia 
coli, purified and characterized by SDS-PAGE, absorbance and circular dichroism techniques which confirmed 
that the enzymes are correctly folded and bind the respective prosthetic groups (Figure S4 of Suppl. Information).
We used metabolomics to follow directly the conversion of L-Cys into the final products, which are respec-
tively cystathionine and pyruvate for CBS and CSE. This strategy, which relies on high accuracy techniques such 
Figure 2. Comparison of the inhibition of compound 2a and PAG by assessment of H2S production 
in mouse aorta homogenates. The conditions for H2S determination were chosen according to previous 
protocols17. Homogenized aorta was incubated with different concentrations of compounds for 30 minutes 
and added to the reaction mixture. ZnAc (1%, 250 μ L) was added to trap H2S followed by TCA (10%, 250 μ L) 
and N,N-dimethyl-p-phenylenediamine-sulfate (20 μ M, 133 μ L). Absorbance was measured at a wavelength of 
670 nm after 20 minutes. All samples were assayed in duplicate and compared to a calibration curve of NaHS. 
Basal values refers to H2S measurement in absence of L-Cys and it represents the endogenous production of 
H2S. Vehicle represents the used buffer, containing L-Cys.
Figure 3. Measurement of L-Cys induced vasorelaxation. (A,B) The assay was repeated at the concentration 
at which 2a and PAG exert maximal inhibition. N = 6 rings harvested from 6 different animals for each group of 
experiments. Vehicle, water.
www.nature.com/scientificreports/
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as nuclear magnetic resonance (NMR) and/or mass spectrometry (MS), has by now been vastly validated for the 
detection of metabolites, enzymatic products and metabolic pathways24,25. Because of its ability to identify all 
products rather than only specific ones, as in the methylene blue assay, metabolomics can powerfully complement 
these assays and provide new information. NMR spectra were recorded to detect the progressive formation of the 
products starting from 15N,13C-labelled substrate. For the reaction catalyzed by CBS, unlabeled L-homocysteine 
was also added as co-substrate. In the interest of following the kinetics at close intervals, we recorded only the first 
increment of 13C HSQC spectra at fixed time intervals (Figure S5 of Suppl. Information). Complete 2D 13C HSQC 
spectra were collected before and after each experiment to confirm completeness of the reactions. The results were 
best visualized as a pseudo 3D experiment in which each spectrum is plotted along the x and y axes and the third 
axis reflects time (Fig. 4).
In the control kinetics of CBS catalyzed production of L-cystathionine (Fig. 4A), the 15N,13C-labelled L-Cys 
resonances gradually decrease up to complete disappearance, while new resonances increase in intensity. The 
expected cystathionine resonances were not all detected, because of the unlabeled homocysteine contribution. In 
the control kinetics of the CSE-catalyzed reaction, the 15N,13C, L-Cys peaks decrease up to complete disappear-
ance, while the pyruvate product increases (Fig. 4B). The presence of compound 2a solutions pre-incubated with 
CBS did not alter the kinetics and the reaction proceeded with the practically complete conversion of L-Cys to 
L-cystathionine (Fig. 4C), whereas inhibited CSE catalyzed pyruvate production (Fig. 4D). These results conclu-
sively prove that compound 2a is a powerful inhibitor selective for CSE with no effects on the kinetics of CBS.
Figure 4. Enzymatic kinetics followed by metabolomics. Pseudo 3D plots of CBS and CSE enzymatic 
kinetics. The data are presented as pseudo 3D plots where the first increment of 13C HSQC spectra is plotted 
along the x (F2) and y axes. Time is plotted on the third axis. The first spectrum was obtained ~2 min after the 
addition of the enzyme, and subsequently 59 spectra were collected over a 300 min period. Kinetics of control 
isolated CBS (A) and CSE (B). Time course of CBS (C) and CSE (D) in the presence of compound 2a (250 μ M).  
Disappearance of the resonance at 3 ppm testifies conversion of L-cysteine to L-cystathionine by CBS and to 
pyruvate by CSE. The spectra were recorded at 800 MHz and 37 °C using L-Cys concentrations of 250 μ M. 
Enzyme concentrations of 20 μ M.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:34398 | DOI: 10.1038/srep34398
Metabolomics reveals the limitations of the methylene blue assay. During our NMR based 
metabolomics studies we observed something peculiar: when PAG was used in the NMR assay, no appreciable 
formation of pyruvate was observed, as expected, but the resonances of L-Cys surprisingly decreased and new 
product resonances, different from pyruvate, appeared and progressively increased (Fig. 5A). This behaviour was 
also confirmed in a 13C 2D HSQC spectrum acquired at the end of the kinetics (Fig. 5B): in the presence of PAG, 
the cysteine resonances at 3.90 ppm (CαH and 55 ppm in the carbon spectrum not shown) and at 3.05 ppm (CβH2 
and 25 ppm) were absent at the end of the reaction. This means that, although PAG inhibits H2S formation, it is 
not able to block cysteine consumption. This is per se an important result which warns us against the inefficacy 
of PAG. New peaks at 3.92 ppm, 3.40 ppm and 3.25 ppm appeared instead (and at 55 ppm, 32 ppm and 32 ppm 
in the carbon spectrum respectively). These chemical shifts were tentatively assigned to cystine, lanthionine or a 
Figure 5. CSE kinetics in the presence of PAG followed by NMR and LC-MS. (A) The data are presented as pseudo 
3D plots where the first increment of 13C HSQC spectra is plotted along the x (F2) and y axes and time is on the third 
axis as in Fig. 4. The concentration of PAG is 250 μ M. (B) The first (blue) and last (red) increments of a 13C HSQC. The 
first spectrum was obtained ~2 min after the addition of the enzyme, and subsequently 59 spectra were collected over a 
300 min period. The conditions used are the same as in Fig. 4. (C) Extracted ion chromatogram of CSE reaction mixture 
in the present of PAG at the end of the reaction, carried out for 60 minutes, by adding L-cysteine and incubating the 
mixture at 37 C. The chromatography was performed by monitoring the MS/MS transition 241.1− > 152.0. The panel 
below the chromatogram reports the MS/MS fragmentation pattern of the peak at retention time of 13.5 min, which 
corresponds to cystine. The injection volumes were 10–20 μ L for each sample.
www.nature.com/scientificreports/
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similar compound. To confirm which of these compounds is the additional product we used the high accuracy 
LC-MS technique25 (Fig. 5C). We found that, during the reaction, a predominant quantity of cysteine is converted 
into cystine with a minor quantity of lanthionine. Identification of this reaction product has so far been over-
looked likely because all previous studies solely relied on the methylene blue assay which allows only detection of 
H2S production. Since the presence of an excess of freshly prepared DTT makes it unlikely chemical formation of 
cystine by oxidation, a possible explanation is that cystine is formed enzymatically.
In vitro assays suggest that the new inhibitor is not suicidal and competitive. We characterized 
the complex of CSE with compound 2a by mass spectrometry to test whether also this inhibitor, like PAG, is sui-
cidal. We found no increase of the mass of CSE suggesting no covalent attachment of compound 2a (Figure S6 of 
Suppl. Information). This result agrees with the suggested mechanism of inhibition which postulates the need of 
a NH2 group for the reaction to occur13. To quantify the inhibitory potency towards CSE of compound 2a with 
respect to PAG, we used an adapted version of a previously described spectrophotometric assay17. The IC50 meas-
ured on the purified protein is 6.3 ± 1.0 μ M for 2a versus 42.2 ± 1.1 μ M for PAG (Figure S7 of Suppl. Information). 
This value is in excellent agreement with the data from the ex vivo assay.
With the same spectrophotometer assay described above, we also determined the Michaelis-Menten constants 
Vmax, the maximum reaction rate at maximum saturation of the substrate concentration, and Km, the substrate 
concentration at which the reaction rate is half of Vmax, at different concentrations (0–20 μ M) by nonlinear regres-
sion analysis using the Michaelis-Menten equation (Fig. 6A). The Km value is 1.1 ± 0.1 mM, instead the Km,apparent 
values at various concentrations of compound 2a (5 μ M, 10 μ M and 20 μ M) are 1.5 ± 0.1 mM, 1.9 ± 0.3 mM and 
2.8 ± 0.3 mM, respectively. The Vmax is 0.50 ± 0.02 U/mg at all the tested concentrations of the inhibitor. These 
kinetic parameters suggest that compound 2a is a competitive inhibitor of the enzyme. Furthermore, the slopes 
from the double reciprocal plot are plotted in a secondary plot vs. the concentrations of inhibitor used (Fig. 6B). 
The intercept and the slope of this graph is Km/Vmax and Km/(Vmax Ki), respectively, thus, the Ki is 13 μ M.
While a more thorough enzymatic characterization will be needed, these data suggest the mechanism of 
action of the new inhibitor which has quite distinct properties from PAG.
Figure 6. Enzymatic characterization of the effects of compound 2a on purified CSE. (A) Lineweaver–
Burk plot of CSE catalyzed H2S production in the absence (control) and presence of various concentrations 
of compound 2a (5 μ M, 10 μ M and 20 μ M). The data suggest that 2a is a competitive inhibitor, since the 
plots are linear and intersect at the y-axis (Km increases while Vmax remains unaffected). For reference, non-
competitive inhibition would produce plots with the same x-intercept as uninhibited enzyme (Km is unaffected) 
but different slopes and y-intercepts. Uncompetitive inhibition would cause different intercepts on both the 
y- and x-axes. The estimated Vmax and Km values are 0.50 ± 0.02 U/mg and 1.1 ± 0.1 mM. The Km, apparent values 
are 1.5 ± 0.1 mM, 1.9 ± 0.3 mM and 2.8 ± 0.3 mM for the data at 0 mM, 5 μ M, 10 μ M and 20 μ M of inhibitor, 
respectively. (B) Slopes of the double reciprocal plot vs. the concentrations of inhibitor (0, 5, 10 and 20 μ M)  
(Fig. 6B). The intercept gives the value of Km/Vmax and the slope is Km/(Vmax Ki). Ki is obtained as the intercept/
slope ratio.
www.nature.com/scientificreports/
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Rationalizing the results. We rationalized our findings analysing the structure of CSE. Starting from the 
coordinates of CSE (PDB code 3cog) which contain the covalently bound PAG, we built in manually the coordi-
nates of compound 2a using the software MAESTRO (Schroedinger, LLC, New York, NY). The cavity which con-
tains PAG in the active site, which is also where the substrate cysteine should bind, is big enough to accommodate 
also compound 2a (Fig. 7).
This can easily form multiple interactions with the surrounding groups and hydrogen bond with the side 
chains of Ser63, Tyr114, Gly116, Arg119, Asn241, and Ser358. Amongst these interactions, particularly important 
would be those formed by the carbonyl group of the L-2-oxothiazolidine moiety which could form a bifurcated 
hydrogen bond with Gly116 and Ser358. The triple bond would occupy a position similar (<2A difference) to 
that of PAG without being covalently bound and could not easily be replaced because the pocket between the 
two tyrosines is very deep and narrow. A triple bond forms a long thin “rod” of very small van der Waals radius 
which could thus fit in, while double or single bonds could not be allocated between the tyrosines for lack of 
space. Pi-stacking of the triple bond with the two tyrosine rings could additionally contribute to the stability of 
the interaction.
This configuration would also explain why compounds 1 and 1a do not fit: they have no carboxy group which 
makes the ring to be bent while it is quite flat in 2a and this prevents the possibility of hydrogen bonding to the 
carbonyl oxygen. The bent ring will most likely not fit in the pocket. Compounds 3 and 3a have a CH2 linker 
which positions the ring too far from the pocket to form interactions and changes its angle relative to the triple 
bond. Compounds 4 and 4a are simply too big for the pocket.
We can thus conclude that we have identified a new compound which has all features to optimally fit in CSE 
and inhibit selectively its function.
Conclusion
Investigation of the pathophysiological and pharmacological roles of hydrogen sulfide has rapidly become an 
important research field still widely unexplored which is attracting increasing attention. H2S is now accepted as a 
novel gasotransmitter of potential importance in several areas from asthma to cancer, impotence and stroke26. A 
major obstacle in the rapid development of this field has however been the lack of pharmacological tools such as 
selective enzymatic inhibitors which would allow the study of only one among the several possible pathways. The 
already established inhibitors exhibit low potency and selectivity. We have thus aimed at developing more specific 
and potent inhibitors of CBS and CSE towards H2S production. We used a semi-rational strategy which combines 
two highly successful routes, the structural based and the fragment-based approaches and went all way from 
drug design to ex vivo and in vitro studies. We identified an oxothiazolidine derivative which showed maximal 
inhibitory effects in tissue and proved to be more efficient than PAG and completely selective for CSE by metab-
olomics assays on the purified enzymes. As compared to PAG, the new compound has a significant difference: 
both compounds inhibit CSE from producing pyruvate, ammonia and hydrogen sulfide, but surprisingly, in the 
presence of PAG, CSE remains able to consume the substrate L-Cys and produces cystine and lanthionine. This is 
an important result previously under looked. In contrast, compound 2a inhibits the enzyme completely, keeping 
the concentration of substrate unaffected. This finding suggests the possibility of using lower doses of compound 
2a compared to PAG, consequently also reducing all possible adverse effects. PAG is also a suicidal inhibitor while 
2a does not bind irreversibly offering a further advantage.
In conclusion, it is clear that before using the new compound for human treatment, it will be essential to 
carry out a careful pharmacological study to assess whether the new compound is toxic or is associated with any 
unwanted side effects. For the time being, we are nevertheless confident that identification of this highly selective 
CSE inhibitor will help to better define the role of CSE vs CBS in the pathophysiology of the diseases where a role 
Figure 7. Structural model of compound 2a (stick representation) docked in the coordinates of CSE 
(transparent surface and side chains of nearby residues) in complex with PAG (not shown here). A space-filling 
representation is used for the enzyme surface, coloured according to the electrostatic charge. The compound is 
shown with a stick representation. The enzyme structure (3cog) was drawn with the graphic software MAESTRO.
www.nature.com/scientificreports/
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for the H2S pathway has been proposed. Furthermore, the development of such agents, particularly water-soluble, 
will allow us to evaluate the cross-talk of H2S pathways with other relevant pathways (e.g. NO, COX).
Experimental section
Compound synthesis and their identification. The synthesis strategy is detailed below and summarized 
in Figures S1 and S2 of Suppl. Information. The identity of the resulting products was proven using mass spectrom-
etry, 1H and 13C NMR. All compounds resulted correctly synthesized. Melting points, determined using a Buchi 
Melting Point B-540 instrument, are uncorrected and represent values obtained on recrystallized or chromatograph-
ically purified material. 1H-NMR spectra for compound characterization were recorded on a Varian Mercury Plus 
400 MHz instrument and in DMSO solutions. Chemical shifts are reported in ppm using Me4Si as internal standard. 
The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), 
q (quartet), qt (quintet), dd (double doublet), m (multiplet). Mass spectra of the final products were performed on 
API 2000 Applied Biosystem mass spectrometer. Elemental analyses were carried out on a Carlo Erba model 1106. 
Analyses indicated by the symbols of the elements were within ± 0.4% of the theoretical values. All reactions were fol-
lowed by TLC, carried out on Merck silica gel 60 F254 plates with fluorescent indicator and the plates were visualized 
with UV light (254 nm). Preparative chromatographic purifications were performed using silica gel column (Kieselgel 
60). Solutions were dried over Na2SO4 and concentrated with a Buchi R-114 rotary evaporator at low pressure.
Isolated mouse aortic ring assay. The animals were sacrificed according to the regulations of University 
of Naples. Thoracic aorta from CD-1 mice was rapidly dissected and cleaned from fat and connective tissue. 
Animal care was in accordance with Italian and European regulation on the protection of animals used for exper-
imental and other scientific purposes. For endothelium-denuded rings, the endothelial layer was removed by 
gently rubbing the internal surface of the vascular lumen. Rings of 1.5–2 mm length were cut and mounted in iso-
lated organ baths filled with gassed Krebs solution containing (in mol/L) NaCl 0.118, KCl 0.0047, MgSO4 0.0023, 
KH2PO4 0.0012, CaCl2 0.0025, NaHCO3 0.025 and Glucose 0.010) (95% O2 + 5% CO2) at 37 °C linked to isomet-
ric force transducers (UgoBasile, Comerio, Varese, Italy). Rings were initially stretched until a resting tension 
of 1.5 g was reached and equilibrated for at least 45 min during which tension was adjusted to 1.5 g. The bathing 
solution was periodically changed. In each experiment, rings were contracted with L-phenylephrine (PE) at 3 μ 
mol/L and then at 1 μ mol/L until response was reproducible. To verify the integrity of the endothelium, aortic 
rings were contracted with PE (1 μ M), once plateau was reached and a cumulative concentration-response curve 
to commercially available precursors or the newly synthesized compounds (10 nM – 300 μ M) was performed. 
The rings were contracted with PE (1 μ M) and a cumulative concentration-response curve to L-cysteine (1 μ M 
- 3 mM) was performed. All data are presented as means ± SEM. Statistical analysis was performed by two-way 
ANOVA followed by Bonferroni multiple comparison test. Differences were considered statistically significant 
when P-value was < 0.05. GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was used for 
all the statistical analysis. IC50 values were determined ex vivo, using at least three different concentrations of the 
tested compounds. All the experiments were performed in triplicate. The obtained data, expressed in semiloga-
rithmic scale, were used by the ED50 Plus v1.0 online software to get the IC50 values. All experimental protocols 
were approved by the licencing committee of University of Naples.
Estimate of the Lipophilic parameters. To estimate the plasma membrane crossing properties of the new 
inhibitor, the Log PN values, i.e. partition coefficients n-octanol/aqueous phase of the neutral form of selected com-
pounds, were calculated (c logP) by the program ClogP for Windows version 2.0 (Biobyte Corp., Claremont, CA).
Measurement of H2S production: methylene blue assay. H2S determination was performed, ex vivo 
and in vitro, modifying previous protocols17.
For the ex vivo assay, thoracic aorta was dissected, placed in sterile phosphate buffer solution and cleaned of fat 
and connective tissue. The aortic rings were homogenized in a lysis buffer (potassium phosphate buffer 100 mM pH 
7.4, sodium orthovanadate 10 mM and protease inhibitor) and treated with the different concentrations of com-
pounds for 30 minutes and added in a reaction mixture (total volume 500 μ L) containing piridoxal-5’-phosphate 
(2 mM, 20 μ L), L-cysteine (10 mM, 20 μ L) and saline (30 μ L). The reaction was initiated by transferring tubes from 
ice to a water bath at 37 °C. ZnAc (1%, 250 μ L) was added to trap evolved H2S followed by TCA (10%, 250 μ L) 
and N,N-dimethyl-p-phenylenediamine-sulfate (20 μ M, 133 μ L) in 7.2 M HCl and FeCl3 (30 μ M, 133 μ L) in 1.2 M 
HCl were added. After 20 minutes absorbance values were measured at a wavelength of 670 nm. All samples were 
assayed in duplicate and H2S concentration was calculated against a calibration curve of NaHS (3.12–250 μ M). Basal 
release of H2S was measured in absence of L-Cys. Vehicle indicates the used buffer, containing exogenous L-Cys.
For the in vitro assay, each reaction mixture (250 μ L) consisted of 5 μ g of human CSE, 0.01 mM PLP, 1 mM 
L-cysteine and 50 mM sodium phosphate pH 8.2 buffer. The inhibitors, at different concentrations, were added to 
each reaction 15 min before L-cys was added to the solution. Reaction was initiated by transferring the Eppendorf 
tubes, tightly parafilmed, from ice to a 37 °C water bath. After 30 min of incubation, the evolved H2S was trapped 
via addition of ZnAc (1% w/v, 100 μ L) and proteins were precipitated via addition of TCA (10% w/v, 100 μ L). 
Subsequently, N,N-dimethyl-p-phenylenediamine-sulfate in 7.2 M HCl was immediately followed by addition 
of FeCl3 in 1.2 M HCl, for development of methylene blue. The amount of H2S produced was determined via 
absorbance measurements of the centrifugal supernatants. The absorbance of the resulting solution was measured 
at 670 nm and the amount of H2S was calculated against a calibration curve of standard H2S solutions.
The determination of IC50 on purified CSE was done by a concentration-response curve obtained by plotting 
the percentage of inhibition versus the logarithm of inhibitor concentrations. The IC50 values were estimated from 
the resulting graph using GraphPad Prism v.6.07 (GraphPad Software, Inc. La Jolla, CA).
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Protein expression and purification. E. coli BL21 (DE3) Codon Plus was used as the host strain to 
express recombinant human CSE or CBS. CSE cDNA was cloned into pGEX-4T3 and CBS into pGEX-Kg to 
create N-terminal GSH-S-transferase (GST) fusion proteins. The expression vectors were transformed and plated 
on LB-agar plates, supplemented with ampicillin (100 mg·mL−1). The expression and purification of CBS and CSE 
was adapted from previously described protocols21. Colonies of pGEX-Kg/GST-CBS or pGEX-4T3/GST-CSE 
transformed BL21 cells were separately inoculated into 100 mL of steam-autoclaved Luria-Bertani (LB) broth 
supplemented with 100 μ g/mL of ampicillin (LB-Amp100), and incubated at 37 °C overnight shaking. After 
induction and harvesting, the lysates were centrifuged at 16000 rpm for 30 min at 4 °C using a Beckman JA20 
rotor. The soluble fractions were loaded onto Glutathione sepharose 4B columns equilibrated with binding buffer 
PBS. The flow-throughs were collected, and the beads washed. Proteins attached to the columns were eluted with 
five column volumes of elution buffer (50 mM Tris–HCl, 10 mM reduced GSH, 5mM DTT, pH 8.0), dialyzed 
and concentrated in 10 mM sodium phosphate buffer pH 8.2 and DTT 1 mM. The eluates were passed through 
a Superdex-200 column connected to the AKTA purifier FPLC equilibrated in the same buffer at a flow rate of 
1 mL/min. Fractions containing the enzymes were identified by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE), pooled together and concentrated using an ultra-centrifugal filter (Millipore Amicon 
Ultra-4 10000 MWCO) at 4 °C.
Structural characterization of recombinant enzymes. Far-UV CD measurements were performed on 
a J-715 spectropolarimeter (JASCO, Oklahoma City, OK) equipped with a PTC-348 Peltier temperature control 
system using an enzyme concentration of 4 μ M in 10 mM sodium phosphate pH 8.2 buffer. The spectra were 
recorded in quartz cuvettes (Hellma, Plainview, NY) with path-lengths of 1 mm and averaging five separate wave-
length scans on independent protein preparations to ensure reproducibility. Baseline correction was performed 
by subtraction of the appropriate buffer spectrum. Adsorbance spectroscopy was carried out on a Varian Cary 50 
Bio UV-Visible Spectrophotometer. Measurements were performed in a 1 cm cuvette cell and monitored spectro-
scopically from 650nm to 250 nm.
Enzymologic analysis. Kinetics studies were performed using an adapted version of a spectrophotometric 
assay described by Stipanuk and Beck17. Assay mixtures (250 μ L) contained 5 μ g of purified CSE, 2 mM PLP and 
L-cysteine (1–4 mM) previously incubated at 37 °C. For each L-cysteine substrate concentration, the amount of H2S 
was measured every 3 min over 30 min. Zinc acetate (1% w/v) was added to trap the produced H2S gas. The enzy-
matic reaction was stopped by the addition of 10% (w/v) trichloroacetic acid. N,N-dimethyl-p-phenylenediamine 
dihydrochloride dye (20 mM) and 30 mM FeCl3 were added and the absorbance at 670 nm was measured using a 
microplate reader (Thermo Scientific). All determinations were carried out in triplicates. The amount of H2S pro-
duced was calculated against a calibration curve of sodium hydrosulfide (0–250 μ M). The initial reaction velocity, 
V0 (units/mg of human CSE, where 1 unit is the amount of enzyme that catalyses the reaction of 1 μ mol of H2S 
per minute) was plotted against the cysteine substrate concentration [S]. Rates were fit with the Michaelis-Menten 
equation using GraphPad Prism software version 7 for Windows (San Diego, USA).
NMR spectroscopy. Samples were composed of 15N,13C-L-cysteine (125 μ L, 1 mM), unlabeled L-homocysteine 
(125 μ L, 1 mM) (added only for the CBS time course as co-substrate), DTT (0.5 μ L, 1M), D2O (50 μ L), and enzyme 
(100 μ L, 110 μ M) in 10 mM sodium phosphate pH 8.2 and filled to a final volume of 500 μ L. NMR experiments 
were performed at 300 K on a Bruker AVANCE spectrometer operating at 800 MHz with TCI Cryoprobes. Controls 
were run excluding either the enzyme or the tested compounds pre-incubated with each enzyme. For each sample, 
pseudo-2D experiments were collected in which the first increment of a 13C HSQC spectrum was acquired with 
5 minutes repetition time for a total of 60 spectra, using 15N,13C, L-cysteine and unlabeled L-homocysteine as CBS 
substrate and 15N,13C, L-cysteine as a unique substrate for CSE enzyme. 2D 1H,13C HSQC spectra were acquired 
before and after the enzyme reaction was completed.
HPLC-ESI-MS/MS Analyses. Chromatographic analyses were performed using a HPLC Agilent 1100 series 
equipped with an auto-sampler coupled online with an Agilent LC-MSD SL quadrupole ion trap. The liquid chro-
matography separation was carried out on a Supelco Discovery-C8 column (250 × 3.0 mm, particle size 5 μ m) 
eluted isocratically with 0.1% formic acid in water, at a constant flow rate of 0.1 mL/min. The injection volumes 
were 10–20 μ L for each sample. Electrospray ionization (ESI) was in positive ion mode, with nitrogen as the 
nebulizing and drying gas using a pressure of 30 psi, a drying temperature of 350 °C and drying gas at 7 L/min. 
The ion charge control (ICC) was applied with the target set at 30000 and maximum accumulation time at 20 ms. 
Optimization of instrumental parameters was performed by continuous infusion of 5 μ M standard solution in 
0.1% formic acid. Mass cutoff and amplitude were optimized to obtain the most efficient MS/MS transitions 
from the positively charged precursor ion [M + H]+ to the fragment ions. Multiple reaction monitoring (MRM) 
was used with the MS/MS transitions utilized for the quantitation of analytes of 209.1→ 120 for lanthionine, 
241.0→ 152 for cystine, 122.0→ 105 for cysteine. Quantitation was achieved by comparison with calibration 
curves obtained from standard solutions. Measurements were performed from the peak area of the extracted ion 
chromatogram (EIC). Retention times and peak areas of the monitored fragment ions were determined by the 
Agilent software Chemstation version 4.2.
Structural analysis. Structural analysis and manual docking was possible with the support of the software 
PYMOL and MAESTRO (Schroedinger, LLC, New York, NY). The position of PAG in the X-ray structure 3cog 
was taken as pose of reference.
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